Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPX203 (Crexont) open-label extension in Parkinson's disease
NCT03877510Phase 3Completed
- Sponsor
- Impax Laboratories
- Start
- Apr 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of levodopa in Parkinson's disease (PD), sponsored by Impax Laboratories. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events at 9 months. Started Apr 2019; status: completed.
02
Drugs
levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03877510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03877510.